Aprotinin use in cardiac surgery patients at low risk for requiring blood transfusion

Pharmacotherapy

Volumn 27, Issue 7, 2007, Pages 988-994

  Kristeller, Judith L ^a   Stahl, Russell F ^b   Roslund, Brian P ^a   Roke Thomas, Marie ^a  

^a WILKES UNIVERSITY   (United States)

^b P   (United States)

Author keywords

Aprotinin; Blood transfusion; Cardiac surgery; Cardiopulmonary bypass; Open heart surgery

Indexed keywords

AMINOCAPROIC ACID; APROTININ;

ADULT; AGED; ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION; CONTINUOUS INFUSION; CONTROLLED STUDY; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ERYTHROCYTE CONCENTRATE; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART SURGERY; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; STROKE; UREMIA;

6-AMINOCAPROIC ACID; AGED; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; FEMALE; HUMANS; MALE; MIDDLE AGED; SERINE PROTEINASE INHIBITORS;

EID: 34250874377     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.7.988     Document Type: Article

References (23)

1. Arora RC, Legare JF, Buth KJ, Sullivan JA, Hirsch GM. Identifying patients at risk of intraoperative and postoperative transfusion in isolated CABG: toward selective conservation strategies. Ann Thorac Surg 2004;78(5):1547-54.
2. Graves EJ. National hospital discharge survey: annual summary, 1991. Vital Health Stat 1993;13(114):1-62.
3. Scott BH, Seifert FC, Glass PS, Grimson R. Blood use in patients undergoing coronary artery bypass surgery: impact of cardiopulmonary bypass pump, hematocrit, gender, age, and body weight. Anesth Analg 2003;97(4):958-63.
4. Murkin JM, Lux J, Shannon NA, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994;107(2):554-61.
5. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92(8):2236-44.
6. Kalangos A, Tayyareci G, Pretre R, Di DP, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994;8(12):651-6.
7. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency: a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107(2):543-51.
8. Frumento RJ, O'Malley CM, Bennett-Guerrero E. Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg 2003;75(2):479-83.
9. Murkin JM. Attenuation of neurologic injury during cardiac surgery. Ann Thorac Surg 2001;72(5):S1838-44.
10. Harmon DC, Ghori KG, Eustace NP, O'Callaghan SJ, O'Donnell AP, Shorten GD. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can J Anaesth 2004;51(10):1002-9.
11. Henry DA. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 1999;(1):CD001886.
12. Chu MW, Wilson SR, Novick RJ, Stitt LW, Quantz MA. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann Thorac Surg 2004;78(5):1536-41.
13. Ferraris VA, Ferraris SP. Limiting excessive postoperative blood transfusion after cardiac procedures: a review. Tex Heart Inst J 1995;22(3):216-30.
14. Moskowitz DM, Klein JJ, Shander A, et al. Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center. Ann Thorac Surg 2004;77(2):626-34.
15. Cosgrove DM III, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54(6):1031-6.
16. Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K, Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg 1997;114(2):261-9.
17. Lemmer JH Jr, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996;62(6):1659-67.
18. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005;2(3):218-29.
19. Harder MP, Eijsman L, Roozendaal KJ, van OW, Wildevuur CR. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 1991;51(6):936-41.
20. Lass M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A. Aprotinin in elective primary bypass surgery: graft patency and clinical efficacy. Eur J Cardiothorac Surg 1995;9(4):206-10.
21. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354(4):353-65.
22. Ferraris VA, Bridges CR, Anderson RP. Aprotinin in cardiac surgery. N Engl J Med 2006;354(18):1953-7.
23. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006;46(3):327-38.